Madhav V Dhodapkar

List of Publications by Year
in descending order

83 papers	4,697 citations	126708 33 h-index	102304 66 g-index
83 all docs	83 docs citations	83 times ranked	8713 citing authors

#	Article	IF	Citations
1	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. OncoImmunology, 2016, 5, e1071008.	2.1	545
2	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
3	Combination Therapy with Antiâ€“CTLA-4 and Antiâ€“PD-1 Leads to Distinct Immunologic Changes In Vivo. Journal of Immunology, 2015, 194, 950-959.	0.4	362
4	Natural Killer T Cells in Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1178.	2.2	186
5	Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. New England Journal of Medicine, 2016, 374, 555-561.	13.9	167
6	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 1928-1937.	0.8	148
7	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, 2018, 3, .	2.3	140
8	Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood, 2008, 112, 1308-1316.	0.6	136
9	MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood, 2016, 128, 2599-2606.	0.6	133
10	Selective blockade of the inhibitory FcÎ³ receptor (FcÎ³RIIB) in human dendritic cells and monocytes induces a type I interferon response program. Journal of Experimental Medicine, 2007, 204, 1359-1369.	4.2	132
11	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nature Medicine, 2016, 22, 1351-1357.	15.2	132
12	Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood, 2015, 125, 1256-1271.	0.6	119
13	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
14	Precancer Atlas to Drive Precision Prevention Trials. Cancer Research, 2017, 77, 1510-1541.	0.4	116
15	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight, 2016, 1, e88955.	2.3	111
16	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer Journal, 2019, 9, 94.	2.8	104
17	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood, 2015, 125, 4042-4051.	0.6	103
18	Type II NKT Cells and Their Emerging Role in Health and Disease. Journal of Immunology, 2017, 198, 1015-1021.	0.4	102

#	Article	IF	Citations
19	Daratumumab in multiple myeloma. Cancer, 2019, 125, 2364-2382.	2.0	100
20	Targeting human dendritic cells in situ to improve vaccines. Immunology Letters, 2014, 162, 59-67.	1.1	88
21	ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. Journal of Clinical Investigation, 2016, 126, 3905-3916.	3.9	81
22	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 1541-1554.	3.2	79
23	Trial watch: Dendritic cell-based anticancer therapy. OncoImmunology, 2014, 3, e963424.	2.1	62
24	Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Groupâ€“directed intergroup trial S9003. Blood, 2009, 113, 793-796.	0.6	60
25	Conditional overexpression of TGFÎ²1 promotes pulmonary inflammation, apoptosis and mortality via TGFÎ²R2 in the developing mouse lung. Respiratory Research, 2015, 16, 4.	1.4	54
26	Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges. Clinical Immunology, 2011, 140, 160-166.	1.4	51
27	Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Frontiers in Immunology, 2018, 9, 2204.	2.2	45
28	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica, 2015, 100, 1214-1221.	1.7	44
29	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood, 2021, 137, 3604-3615.	0.6	44
30	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight, 2020, 5, .	2.3	43
31	Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight, 2018, 3, .	2.3	43
32	Nanoparticle-Mediated Combinatorial Targeting of Multiple Human Dendritic Cell (DC) Subsets Leads to Enhanced T Cell Activation via IL-15â€“Dependent DC Crosstalk. Journal of Immunology, 2014, 193, 2297-2305.	0.4	39
33	Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 296-304.e2.	0.2	39
34	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer, 2019, 125, 416-423.	2.0	36
35	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of Clinical Oncology, 2022, 40, 3057-3064.	0.8	31
36	Immunity to stemness genes in human cancer. Current Opinion in Immunology, 2010, 22, 245-250.	2.4	30

#	Article	IF	Citations
37	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. British Journal of Haematology, 2018, 182, 495-503.	1.2	30
38	Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Frontiers in Bioscience - Landmark, 2009, Volume, 796.	3.0	29
39	Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular Genetics and Metabolism, 2020, 129, 286-291.	0.5	28
40	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
41	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2022, 40, 3020-3031.	0.8	26
42	Game of Bones: How Myeloma Manipulates Its Microenvironment. Frontiers in Oncology, 2020, 10, 625199.	1.3	24
43	Risk-associated alterations in marrow T cells in pediatric leukemia. JCI Insight, 2020, 5, .	2.3	23
44	Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).. Journal of Clinical Oncology, 2020, 38, 8507-8507.	0.8	22
45	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
46	Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19. Blood Cancer Discovery, 2021, 2, 9-12.	2.6	20
47	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of Clinical Oncology, 2022, 40, 3808-3816.	0.8	19
48	SOHO State of the Art Updates and Next Questions: T-Cellâ€“Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptorâ€“Modified T Cells and Bispecific T-Cellâ€“Engaging Agents. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 537-544.	0.2	18
49	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
50	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.. Journal of Clinical Oncology, 2019, 37, 8001-8001.	0.8	17
51	MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. Blood, 2018, 131, 2500-2501.	0.6	16
52	Vaccines Targeting Cancer Stem Cells. Cancer Journal (Sudbury, Mass), 2011, 17, 397-402.	1.0	15
53	Tissue-resident memory-like T cells in tumor immunity: Clinical implications. Seminars in Immunology, 2020, 49, 101415.	2.7	15
54	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood Cancer Discovery, 2021, 2, 600-615.	2.6	15

#	Article	IF	Citations
55	Role of chaperones and FcÎ³R in immunogenic death. Current Opinion in Immunology, 2008, 20, 512-517.	2.4	13
56	Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges. Cancer Immunology, Immunotherapy, 2011, 60, 413-418.	2.0	11
57	Hematologic Malignancies: Plasma Cell Disorders. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 561-568.	1.8	11
58	Smoldering Myeloma and the Art of War. Journal of Clinical Oncology, 2020, 38, 2363-2365.	0.8	10
59	Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7944-7945.	3.3	8
60	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American Journal of Hematology, 2021, 96, E68-E71.	2.0	7
61	Personalized Immune-Interception of Cancer and the Battle of Two Adaptive Systemsâ€"When Is the Time Right?. Cancer Prevention Research, 2013, 6, 173-176.	0.7	6
62	Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?. Frontiers in Immunology, 2019, 10, 2385.	2.2	6
63	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia, 2022, 36, 591-595.	3.3	6
64	A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).. Journal of Clinical Oncology, 2017, 35, TPS8053-TPS8053.	0.8	3
65	Safety and Efficacy of Evomelaâ„¢ in Myeloma Autotransplants. Blood, 2018, 132, 3446-3446.	0.6	2
66	Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 2018, 132, 3294-3294.	0.6	2
67	Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group. Blood, 2013, 122, 3174-3174.	0.6	2
68	Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy.. Journal of Clinical Oncology, 2022, 40, 8064-8064.	0.8	2
69	Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).. Journal of Clinical Oncology, 2022, 40, 8054-8054.	0.8	2
70	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. Blood, 2018, 132, 3241-3241.	0.6	1
71	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. Blood, 2012, 120, 4079-4079.	0.6	1
72	Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. Blood, 2015, 126, 120-120.	0.6	1

#	Article	IF	Citations
73	FluzoneÂ® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood, 2015, 126, 3058-3058.	0.6	1
74	Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood, 2016, 128, 2139-2139.	0.6	1
75	The impact of complex karyotype identified by conventional cytogenetics on survival outcomes of 1,000 patients with newly diagnosed myeloma (NDMM).. Journal of Clinical Oncology, 2022, 40, 8063-8063.	0.8	1
76	Reply to N. Biran et al. Journal of Clinical Oncology, 2020, 38, 1368-1369.	0.8	0
77	Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression.. Blood, 2012, 120, 2933-2933.	0.6	0
78	Incidence and Outcomes for Low Risk Myelodysplastic Syndrome: A Surveillance, Epidemiology and End Results (SEER) Study. Blood, 2012, 120, 4944-4944.	0.6	0
79	Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies in Complete Remission (BMB-CR) of Multiple Myeloma (MM) Patients Treated On Total Therapy Protocols â€“ Normalization of GEP Signature in Comparison with Normal Donor BMB (BMB-NL) and Consequences for Progression-Free Survival (PFS). Blood, 2012, 120, 198-198.	0.6	0
80	Dual Face of Immune Microenvironment in Myeloma. Blood, 2014, 124, SCI-50-SCI-50.	0.6	0
81	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3302-3302.	0.6	0
82	Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival.. Journal of Clinical Oncology, 2022, 40, 8062-8062.	0.8	0
83	Analysis of long-term outcomes in R-ISS stage 2 multiple myeloma with and without the presence of high-risk cytogenetics.. Journal of Clinical Oncology, 2022, 40, 8059-8059.	0.8	0